And the Winner Is…

The National Association of Clinical Biochemistry has given a Distinguished Abstract Award to PGXL’s Assistant Lab Director, Dr. Mark Borgman.

Borgman’s The SLC6A4 Long A>G Polymorphism Enhances the Clinical Sensitivity of SSRI Poor-Responder Genotyping showed “that combining SLC6A4 LA/LG with CYP2D6 genotyping improves clinical sensitivity for identifying patients at risk for SSRI therapeutic failure by 12.0% versus SLC6A4 S/L testing alone.”

Bottom line: the addition of PGXL’s SLC6A4 and CYP2D6 genotyping to the diagnosis of depression better identifies patients likely to be non-responsive to commonly prescribed anti-depressants, and may better identify patients likely to benefit from alternative therapies.

To read more on the clinical utility of the serotonin transporter (SLC6A4) and CYP2D6 genotyping, click here.

by Content_Management
This entry was posted in Lab Book. Bookmark the permalink.

Comments are closed.